Aquestive Therapeutics Inc (NASDAQ: AQST) Not A Good Play Anymore?

Aquestive Therapeutics Inc (AQST) concluded trading on Wednesday at a closing price of $4.38, with 3.63 million shares of worth about $15.9 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 212.86% during that period and on April 3, 2024 the price saw a gain of about 5.80%. Currently the company’s common shares owned by public are about 89.97M shares, out of which, 83.74M shares are available for trading.

However, the stock later moved at a day high price of 5.6100, or with a gain of 5.80%. Stock saw a price change of 7.88% in past 5 days and over the past one month there was a price change of 4.78%. Year-to-date (YTD), AQST shares are showing a performance of 116.83% which increased to 284.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.01 but also hit the highest price of $6.23 during that period. The average intraday trading volume for Aquestive Therapeutics Inc shares is 2.14 million. The stock is currently trading -8.35% below its 20-day simple moving average (SMA20), while that difference is up 22.01% for SMA50 and it goes to 94.13% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Aquestive Therapeutics Inc (NASDAQ: AQST) currently have 89.97M outstanding shares and institutions hold larger chunk of about 26.45% of that.

The stock has a current market capitalization of $394.07M and its 3Y-monthly beta is at 2.91. It has posted earnings per share of -$0.14 in the same period. It has Quick Ratio of 1.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AQST, volatility over the week remained 7.23% while standing at 11.90% over the month.

Stock’s fiscal year EPS is expected to drop by -187.91% while it is estimated to increase by 18.51% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on March 28, 2024 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by RBC Capital Mkts stated Aquestive Therapeutics Inc (AQST) stock as an Outperform in their note to investors on April 07, 2021, suggesting a price target of $7 for the stock. On April 22, 2019, H.C. Wainwright Initiated their recommendations, while on January 03, 2019, Lake Street Initiated their ratings for the stock with a price target of $14. Stock get an Outperform rating from RBC Capital Mkts on August 20, 2018.

Most Popular

Related Posts